Classifications

• • C—CHEMISTRY; METALLURGY
  • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
  • C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
  • C11B1/00—Production of fats or fatty oils from raw materials
  • C11B1/12—Production of fats or fatty oils from raw materials by melting out
  • C11B1/16—Production of fats or fatty oils from raw materials by melting out with steam
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
  • A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
  • A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
  • A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
  • A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
  • A23D9/013—Other fatty acid esters, e.g. phosphatides
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
  • A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
  • A23L17/40—Shell-fish
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/56—Materials from animals other than mammals
  • A61K35/612—Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/56—Materials from animals other than mammals
  • A61K35/63—Arthropods
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/56—Materials from animals other than mammals
  • A61K35/63—Arthropods
  • A61K35/64—Insects, e.g. bees, wasps or fleas
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/37—Esters of carboxylic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/55—Phosphorus compounds
  • A61K8/553—Phospholipids, e.g. lecithin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
  • A61K8/925—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of animal origin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/08—Antiseborrheics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/10—Anti-acne agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/06—Antiarrhythmics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
  • A61Q1/12—Face or body powders for grooming, adorning or absorbing
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
  • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/007—Preparations for dry skin
• • C—CHEMISTRY; METALLURGY
  • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
  • C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
  • C11B1/00—Production of fats or fatty oils from raw materials
  • C11B1/02—Pretreatment
• • C—CHEMISTRY; METALLURGY
  • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
  • C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
  • C11B1/00—Production of fats or fatty oils from raw materials
  • C11B1/06—Production of fats or fatty oils from raw materials by pressing
• • C—CHEMISTRY; METALLURGY
  • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
  • C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
  • C11B13/00—Recovery of fats, fatty oils or fatty acids from waste materials
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
  • A61K2800/70—Biological properties of the composition as a whole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
  • A61Q1/02—Preparations containing skin colorants, e.g. pigments
  • A61Q1/04—Preparations containing skin colorants, e.g. pigments for lips
  • A61Q1/06—Lipsticks
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
  • A61Q1/02—Preparations containing skin colorants, e.g. pigments
  • A61Q1/10—Preparations containing skin colorants, e.g. pigments for eyes, e.g. eyeliner, mascara
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02W—CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO WASTEWATER TREATMENT OR WASTE MANAGEMENT
  • Y02W30/00—Technologies for solid waste management
  • Y02W30/50—Reuse, recycling or recovery technologies
  • Y02W30/74—Recovery of fats, fatty oils, fatty acids or other fatty substances, e.g. lanolin or waxes

Definitions

• the present invention relates to a processing layout for obtaining krill oil with polyunsaturated fatty acid DHA and EPA in the phospholipids fraction, with astaxanthin, and neutral lipids coming from the meal processing line, used for human health applications while the resulting krill meal will have a low fat content.
• This invention also discloses a procedure for obtaining a dried complex that contains krill oil in combination with phospholipids linked to DHA and EPA, proteins and astaxanthin for the use on human- health human applications.
• Euphasiaceae living in the pristine Antarctic Ocean that is considered the feed base of the all Antarctic eco-system.
• the Antarctic krill in particular those that live at the Antarctic and sub- Antarctic regions, are composed of 11 Euphasia species, being dominant Euphausia superba, Dana and Euphausia. crystallorophias.
• the lipid content is about 10-26% of the krill dry weight, depending on the season of the year and its sexual maturity as well as body size. Usually the krill fatty period is between March to June each year. The female krill has near double amount of lipids than the male. The lipid concentration increases with age and decreases rapidly after the spawning.
• the main krill lipid fractions include triglycerides, phospholipids, as well as its sterols and esters (Grantham. 1977. Loc. cit; Budzinski et al. 1986. Loc. cit.).
• the average content of phospholipids is about 69% and triglycerides about 26%.
• the krill phospholipids fraction, rich in polyunsaturated fatty acids, particularly 20:5 and 22:6, correspond to approximately 50% of total phospholipids.
• Fricke et al. described that Euphausia superba Dana lipid composition was phosphatidylcholine (33-36%), phosphatidylethanolamine (5-6%), triaeylglycerol (33-40%o), free fatty acids (8-16%) and sterols (1.4-1.7%). Wax esters and sterol esters were present only in traces. More than 50 fatty acids could be identified and the major ones being 14:0, 16:0, 16:l(n-7), 18:l(n-9), 18:l(n-7), 20:5(n-3) and 22:6(n-3). Phytanic acid was found in a concentration of 3% of total fatty acids.
• Clarke described lipid content and composition of the Antarctic krill Euphausia superba.
• Female total lipid content increases during the summer as the ovary matures, and there is also some evidence of an increase in the lipid content of males and immatures as winter approaches.
• the storage lipid is mainly triaeylglycerol and there is less than 1% wax ester.
• Fatty acids are moderately unsaturated, though less so in the ovarian lipid, and the triaeylglycerol contains up to 4% phytanic acid (Clarke A. 1984. Lipid content and composition of Antarctic krill, Euphausia superba Dana. J. Crust. Biol. 4:285-294).
• Phleger et al. described lipid compositions of Antarctic euphausiids, Euphausia superba, E. tricantha, E.frigida and Thysanoessa macrura collected near Elephant Island during 1997 and 1998.
• Total lipid was highest in E. superba small juveniles (16 mg g-1 wet mass), ranging from 12 to 15 mg in other euphausiids.
• Polar lipid 56-81% of total lipid
• triaeylglycerol (12-38%) were the major lipids with wax esters (6%) only present in E. tricantha.
• Cholesterol was the major sterol (80-100% of total sterols) with desmosterol second in abundance (1-18%). 1997 T.
• E. superba EPA, 15-21%; DHA, 9-14%), and were less abundant in other krill.
• Lower levels of 18:4(n-3) in E. tricantha, E.frigida and T. macrura (0.4-0.7% of total fatty acids) are more consistent with a carnivorous or omnivorous diet as compared with herbivorous E. superba (3.7-9.4%).
• Kolakowska described lipid compositions of seven krill Euphausia superba D.) samples, fresh and after various periods of storage at 251 (Kelvin Degrees).
• Fresh krill lipid composition differed from that determined in frozen samples, depending on storage duration, season of harvest, and developmental stage.
• Phospholipids proved most susceptible to changes, as opposed to triglycerides, which were most resistant; diglycerides and cholesterol esters were also destroyed.
• the freezing process per-se affected the lipid composition only slightly; however, after 30 days storage the amount of free fatty acids almost doubled. After 6 months storage at 25 ⁇ , 70% of phospholipids were decomposed and the amount of free fatty acids increased by a factor of 6 to 20.
• crystallorophias were mostly esters of oleic (84%) and palmitoleic (10%) acids with n-tetradecanol (69%) and n-hexadecanol (28%) (Bottino, N.R. 1975. Lipid composition of two species of Antarctic krill: Euphausia superba and E. crystallorophias. Comp Biochem Physiol B. 50:479-484).
• the high content of polyunsaturated fatty acids in the phospholipidic fraction could be necessary to keep the plasmatic membrane fluidity at low temperatures in the Antarctic oceans.
• a high unsaturation level might be required to give the krill phospholipids deposits the necessary plasticity for the animal flectation and motion at low temperatures.
• This process comprises contacting the krill meal with an organic solvent to produce a lipid containing liquid.
• this liquid is extracted with other organic solvents to extract neutral lipids.
• the remaining fraction is a phospholipids enriched fraction.
• GB407729 presented by Johan Olsen Nygaard. This patent describes a method to extract oil from marine animals, in particular whale and other sea mammals, by heating in bath of oil. This document is different from our invention because is not applied to krill and utilizes heated oil for lipid extraction. Our invention does not use heated oil for phospholipids extraction.
• JP2004024060 (Nippon Suisan Kaisha Ltd). This document describes a procedure for obtaining an astaxanthin enriched lipid fraction from Antarctic krill. This document declares a different process from the one declared in the present invention in that the instant process aim is not the astaxanthin production.
• WO2007/080514 Kerman A/S and Alfa Laval Copenhagen A/S
• a method for extracting lipid fractions from krill wherein freshly captured krill is grinded to obtain a slurry, which is gently heated to a temperature below 60°C, preferably bellow 30°C, for less than 45 minutes, thereafter the liquid splits into an aqueous phase and a krill oil phase from which a krill oil extract is derived without the use of organic solvents.
• This document reveals a process different from the one declared in the instant invention as the present procedure does not grind the captured krill before heating. This document is also different since the heating temperature declared in the instant process is >90°C.
• WO2007/080514 is used ultrasound for krill oil separation while the present invention does not use any type of ultrasound technology. It also proposes a simple extraction while the present invention is based in a double-extraction principle.
• WO2007080515 (Aker Biomarine ASA) describes a process for obtaining krill lipids by processing the krill at a temperature below 60°C with mechanical and physical disruption of the lipid cell membrane to facilitate low temperature extraction. This process takes place under inert gas athmosphere to prevent oxidation or denaturation of fat and proteins. Intermediate processing tanks are kept at a minimum level to reduce residence time; and the oil after recovery is immediately frozen to stabilize it.
• This document differs from the present invention since the instant procedure does not grind the captured krill to facilitate lipid extraction, instead a heating temperature of >90°C is used; further the process of the present invention does not use any type of gases or freezing technologies.
• WO2009/027692 (Aker Biomarine ASA), describes a method for krill meal
• This procedure uses a two-step cooking process. In the first step the proteins and phospholipids are removed from the krill and precipitated as a coagulum. In the second stage the krill without phospholipids are cooked. Following this, residual fat and astaxanthin are removed from the krill using mechanical separation methods. In this method, krill is heated to 60-75°C in the presence of water to dissolve/disperse lipids and proteins to the water phase, called krill milk. This krill milk was heated to 95-100°C to remove as a precipitate the krill protein and lipids from the water phase.
• the process declared in the present invention differs from the one declared in this reference, as the krill oil is not separated from the crustacean by precipitation along with proteins and only one step of heating at >90°C is used.
• krill oil is usually enriched in neutral lipids with very low or undetectable amount of phospholipids ( ⁇ 0.5%).
• fresh krill is heated using an indirect heating cooker with rotating screw conveyor, followed by a twin-screw press and drier.
• the press liquid obtained by the twin-screw press is passed through a decanter to remove the insoluble solids.
• the clarified decanter liquid is then used to feed separators centrifuges to separate the krill oil normally enriched with neutral lipids and astaxanthin.
• phospholipids are bound to the proteins in the press cake. Therefore, phospholipids are usually found associated to the krill meal.
• the fat content in the krill meal is usually 16-18%.
• the yield of the neutral lipid-enriched krill oil obtained using the traditional krill meal plant is low, ranging usually between 0.3-1.0% from raw krill.
• This neutral lipid-enriched krill oil contains astaxanthin ranging between 700-1.500 mg/kg depending on the season and the fishing ground catching.
• the non-traditional krill meal plant considered a contherm cooker system, a two-phase decanter or three-phase decanter and a drier. These decanters are used for de-watering and de-fatting the cooked krill.
• the decanter liquid is used to feed the centrifuge separators to obtain usually a neutral lipid-enriched krill oil with low or undetectable levels of phospholipids ( ⁇ 0.5%).
• the phospholipids are also bound to the proteins in the decanter solids. As described above, phospholipids are found in the krill meal.
• the yield of neutral Iipid-enriched krill oil from the non-traditional krill meal plant is much lower, in the fatty period ranging from 0.1 to 0.4% of raw krill.
• a conventional contherm cooker system is used which has inherent agitation (scraped knife). Therefore, the processed krill is agitated and also minced. This agitation/mincing process produce lipid emulsification along with krill proteins and water.
• krill phospholipids catalyze the emulsification because these lipids act as an emulsifier agent. For this reason, using a non-traditional krill meal process, higher lipid content is bound to the decanter solids.
• the fat content of the decanter liquid has a lipid content ranging from 1.0 to 2.5%
• the resultant stickwater has a yellow color and it is emulsified, with a fat content ranging from 0.7 to 1.6%
• the krill meal has a fat content ranging from 20 to 26%
• the krill oil recovery by this non- traditional process is very low.
• the patent application CL 1021 1995 (only Tepual S.A) refers to a method for obtaining krill oil using thermal fractionation and centrifugation.
• This oil obtaining process claims that the fatty acids types and lipids composition can be regulated controlling the krill cooking temperature during the process of oil production. At high cooking temperature (95°C) lower yield of poly-unsaturated and phospholipids fractions were obtained as compared when the cooking temperature was reduced (75°C). Also this oil process claims that main components of its fractional composition correspond to triglycerides being 35 to 96%; and phospholipids from 4 to 28%. The poly-unsaturated fatty acids ranged from 4 to 46%.
• this process used for obtaining krill oil considers krill cooking, pressing the cooked krill and the passing the press liquid through a two-phase decanter to separate the insoluble solids, being the oil separated from the decanter liquid using centrifuge separator. During this process only one type of krill oil was obtained.
• This invention discloses a new on board (at sea) and/or on shore (on land) process for simultaneously obtaining both: a phospholipids enriched krill oil and neutral lipid enriched krill oil containing DHA and EPA poly-unsaturated fatty acids and astaxanthin.
• Antarctic krill oil is particularly rich in DHA and EPA containing phospholipids. Because the amphipathic nature of phospholipids, i.e. a negative charged phosphate group in one end and a hydrophobic lipid in the other end, this lipid is a very potent emulsifier agent.
• Krill grinding and/or mincing induce emulsification of soluble proteins, water, neutral lipids and phospholipids. Therefore, once the emulsion is formed, phospholipids can be obtained from krill mixtures only by organic solvent or C(1 ⁇ 4 supercritical extractions. See WO02/102394 and US2008/0274203 as example.
• a new procedure for phospholipids extraction from fresh krill or other similar crustacean is disclosed. This procedure is based on a process where no grinding, agitation and or mincing of the krill are carried out. Using this method no phospholipids-catalyzed emulsification occurs. Cooking of whole intact krill or fraction produces the release of a liquid from the crustaceans. The oil contained in this liquid is enriched in neutral lipids. The whole and intact krill was further squeezed to obtain a new liquid fraction. The oil obtained by centrifugation of this second fraction is enriched in phospholipids. The resultant squeezed krill is used to obtain a low fat krill meal.
• the present invention allows having a much more controlled extraction process, allowing a dramatic reduction on not-necessary logistic transshipment, raw material and cargo handling.
• Other advantages of the present invention reside in the "finished product" character of the end product on the same premises where capture and processing takes place.
• this patent also applies either if they are farmed or captured crustaceans, such as but not limited to Pandalus borealis, Cervimunida johni, Heterocarpus reedi, Pleuroncodes monodom, Penaeus vannamei, Penaeus monodon, Penaeus stylirostris, Penaeus chinensis, Penaeus. orientalis, Penaeus japonicus, Penaeus indicus, Penaeus merguiensis, Penaeus esculentus, Penaeus setiferus, Macrobrachium spp, and others.
• Pandalus borealis Cervimunida johni, Heterocarpus reedi, Pleuroncodes monodom, Penaeus vannamei, Penaeus monodon, Penaeus stylirostris, Penaeus chinensis, Penaeus. orientalis, Penaeus japonicus, Penaeus indicus, Penaeus
• step b) decanting the cooked krill from step a) using a decanter with high torque to obtain a partially de-fatted and de-watered solid and a decanter liquid;
• step b) squeezing the partially de-fatted and de-watered solid from step b) through a press to obtain a press liquid and a solid fraction;
• step f) optionally, drying the press liquid from step c) to obtain a dried complex of human-grade krill which contains krill oil in combination with phospholipids, DHA, EPA, proteins and astaxanthin.
• this invention also discloses the use of special equipments, wherein such equipments are designed to avoid agitation, mincing, and/or grinding, throughout all processing steps (i.e. cooking, pumping, and so on) to reduce oil emulsification with protein, water and krill phospholipids, acting this last component as the emulsifier agent.
• equipments include screw pumps, continuous cookers with screw conveyor at low speed, belt conveyors, screw conveyors, de-boner, chopper or similar.
• Krill oils obtained using the procedure disclosed in the present invention considering the neutral lipid-enriched krill oil separation from the decanter liquid obtained by using specific centrifuge separators. These centrifuge separators are specifically and only used for the decanter liquid treatment.
• the phospholipids-enriched krill oil is obtained from the press liquid using other specially-designed centrifuge separators. Then the decanter removes important neutral lipids into the decanter liquid and phospholipids are more concentrated in the decanter cake. Therefore, each krill oil type has its own exclusive processing line composed of separators centrifuges, pumps, piping, tanks, heat exchangers and packaging station.
• This invention relates to a method for obtaining specific Krill oils from Krill, preferably from South Antarctic Krill, through a processing preferably made on board (at sea), on board factory trawlers, or mother vessels. Further the present invention is suitable for being carried out on shore (on land) processing plants.
• the final processing target of the processing method disclosed in this invention includes: a) cooking of whole or fraction fresh marine species without agitation and/or mincing; b) decanting of cooked marine species using a two-phase decanter and/or a three-phase decanter or any other type of decanting solution with high torque to obtain a partial de-fatted and de-watered solid and a decanter liquid; c) squeezing of the partial de-fatted and de-watered decanter solid through a simple press and/or using a twin-screw press and/or any other pressing solution to obtain a press liquid and a solid fraction which was further processed to obtain the low fat dried marine-species meal; d) centrifuging of the press liquid to obtain the phospholipids enriched marine-species oil; e) centrifuging of the decanter liquid obtained in step b) to obtain the neutral lipid enriched marine-species oil and stickwater.
• the equipment used in this process allows avoiding agitation throughout
• This invention also discloses a phospholipids-, neutral lipids-, omega-3's- and protein- enriched dried powder, and the use of this product as a heath product for human application, a powerful health-promoter, growth enhancer, immune-system promoter and wellness end-product. All products obtained with the procedure disclosed in this invention are produced by a non-chemical treatment, i.e. a process free of organic solvents and/or C0 2 supercritical fluid, for separating the krill oil.
• the phospholipids enriched krill oil of the present invention is useful for health human application and has a total phospholipids content of about 30 to 70% w/w, more specifically from about 35 to 60% w/w, and even more specifically from about 35 to 55% w/w.
• the DHA and EPA content are from about 10 to 70% w/w, more specifically from about 15 to 60% w/w, and even more specifically from 20 to 55% w/w.
• Neutral lipids content is from 30 to 70% w/w, more specifically from about 40% to 65% w/w, and even more specifically from about 45 to 65% w/w.
• Astaxanthin content is from about 200 to 1.500 mg/kg, more specifically from about 300 to 1.200 mg/kg, and even more specifically from about 400 to 1.000 mg/kg.
• the neutral lipid enriched krill oil of the present invention is also useful for health human application, having a content of neutral lipids from 50 to 100% w/w, more specifically from 60 to 100% w/w, and more specifically from 70 to 100% w/w.
• DHA and EPA content are from 2 to 45% w/w, more specifically from 2 to 40% w/w, and more specifically from 5 to 35% w/w.
• Phospholipids content is less than 10% w/w, more specifically less than 5% w/w, and even more specifically less than 2% w/w.
• Astaxanthin content is from 200 to 1.500 mg/kg, more specifically from 300 to 1200 mg/kg, and even more specifically from 400 to 1.000 mg/kg.
• the phospholipids-etrriched krill oil of the present invention is preferably produced on board (at sea) which provides having the direct advantage of using of a fresh raw krill, this way avoiding freezing of the whole or fraction raw of krill.
• on board processing also produces fresh krill meal, which can eventually be used for further krill oils extraction processes in on shore (on land) processing plants.
• the phospholipids-enriched krill oil of the present invention wherein said product is produced preferably through the on board (at sea) processes, that means the assurance of the use of highly fresh whole or fraction raw krill, avoiding this way the phospholipids decomposition and/or lipids deterioration during the freezing process, frozen
• This invention represents a potent krill-related environment-driven development, as
• this invention guarantees lower processing costs which goes in direct benefit of end- users through a lower end-product selling price
• the biomass protection is also guaranteed as the value-added concept is secured on board (at sea) and does not need extra costs to transport raw material for further on shore (on land) processing.
• This invention allows having end-products secured on board (at sea);
• This invention will also provide a much better resource protection as the catch effort will not be focused on a limited catch and processing period rather spread-out the entire krill fishing season.
• This invention further relates to South Antarctic Krill processing made preferably on board (at sea) factory trawlers or mother vessels, this invention also relates to krill processing made on shore (on land) processing plants whereas the on board (at sea) processing steps prevails on shore (on land) whereas the final processing target of the processing method disclosed in this invention includes:
• This process uses equipments that avoid agitation throughout all steps (i.e. cooking, pumping, and so on) to reduce oil emulsification with protein, water and marine-species phospholipids, acting this last component as the emulsifier agent.
• the krill meal obtained with the process of the present invention has a fat content ranging from 5 to 15%, protein content from 60% to 70%, and moisture content from 6 to 10%.
• both krill oils composition obtained in the present invention are similar to krill oils obtained from other inventions and processes, and the krill oils of this invention are not exposed to the use of any toxic or non-toxic chemicals during the process, the resulting krill oils of this invention could be safely used for human consumption according to the European Food Safety Authority (EFSA) (Scientific Opinion of the Panel on Dietetic Products Nutrition and Allergies on a request from the European Commission of the safety of "Lipid extract from Euphausia superha" as food ingredient. The EFSA Journal (2009). 938, 1-16).
• EFSA European Food Safety Authority
• Human health applications disclosed for the krill oils obtained in the present invention can be for reducing premenstrual symptoms, preventing hypertension, control of blood glucose levels in patients, control of arthritis symptoms, prevention of hyperlipidemia and other health applications.
• Such oils can also be used in preparing dermatologic products, specially topic or systemic products, for treating skin diseases related to a defficiency of essential fatty acids, such as xerotic skin, hyperkeratosis, ictiosis, acne, dermic ulcers, psoriasis, serborreic eczema, atopic dermatitis, among others
• FIG. 1 is a flowchart depicting the process of the present invention.
• FIG. 2 shows the current processing layout using traditional process.
• FIG. 3 shows the current processing layout using non-traditional process.
• the present invention provides systems and processes for processing a marine biomass.
• the marine biomass is krill, preferably the Antarctic krill Euphasia superba.
• Other krill species or crustacean can also be processed using the systems and processes of the present invention. Examples of such species are E.
• the krill is preferably processed in a fresh state as defined herein. Frozen krill is not preferred to be used with the process of the present invention, as ice crystals formed during krill freezing which can disrupt anatomical structures of the crustacean. Destruction of tissues by freezing is a well established subject in the state of art (Whittaker D . 1984. Mechanisms of tissue destruction following cryosurgery. Ann R Coll Surg Engl. 66:313-318).
• the krill is processed fresh on board a fishing vessel either factory trawler, mother factory vessels, or intermediate processor or similar or whatever other ship suitable to carry out the process of this invention within a term of 14, 12, 10, 8, 6, 5, 4, 3, or preferably 2 hours of catching krill.
• the krill is processed on board a ship within 1 hour or preferably 0.5 hours or more preferably wMiin 20 minutes after catching the krill.
• the ship tows a trawl that is configured to catch the krill and/or that the ship receives its krill or other species from fishing vessels or other factory trawlers.
• the krill is then transferred from the trawl to the ship and processed, preferably immediately after krill catching.
• the trawl comprises (either a regular fishing gear composed of trawls and/or purse spuring system and/or) a pumping system to pump the freshly caught krill from the trawl to the ship so the krill can be processed in a fresh state.
• the catch system be it regular trawl or pump system, it is designed in such a manner that no damage, (deterioration) grinding or mincing is done to the krill during the pumping from the trawl to the ship.
• the fresh whole krill or fraction is transported to the cooker using belt conveyor, or screw conveyor or screw pumping or another transport system avoiding krill agitation to avoid the oil emulsification with protein and water.
• the whole krill is cooked in a cooker with indirect and/or direct steam heating or another heating system, but at a low rotation speed of about 1-100 rpm, preferably 2-20 rpm, and more preferably 5-10 rpm, without agitation to avoid the oil emulsification.
• the krill temperature at the exit of the cooker is about 20-100°C, preferably 50-100°C, more preferably 75-100°C and even more preferably 93-95°C, or whatever other temperatures not disclosed here but that are necessary to reach complete protein denaturation.
• the cooker type is not particularly restricted but as preferred embodiment this cooker must operate without agitation for avoiding the emulsification state.
• the cooked krill is transported to the two-phase decanter using a screw conveyor or a screw pumping, or another transporting system without krill agitation for avoiding oil emulsification.
• the cooked krill is passed through a two phase- decanter with high torque about 1-10 kNn, preferably 1.2-5 kNn, more preferably 1.5-3 kNm, even more preferably 1.8-2.5 kNm, and a speed about 100-1000 rpm, preferably 1000-8000 rpm, more preferably 2.000-5.000 rpm, even more preferably 3.000-4.600 rpm, for partial de-watering and partial de-fatting, separating it into a decanter solids phase and a decanter liquid phase.
• a decanter type is not particularly restricted.
• the moisture content of decanter solid is about 40-80%, preferably, 50-70%, more preferably 55-67%, even more preferably 58-65%.
• Table N°l shows the lipid and moisture content of decanter solids and decanter liquids, obtained with krill catch during fatty period using a previous cooker with indirect and direct steam heating with screw conveyor at low rotation speed.
• the decanter solid has a lipid content range of 19,8 to 22,4 % wt dry base, so the resulting krill meal with 8% of moisture from this solid will have a lipid content of about 18,2 % to 20,6%.
• the decanter liquid obtained in such cooker is not emulsified and has higher lipid content compared to the decanter liquid using a conventional contherm cooker.
• Table N°2 shows the lipid and moisture content of decanter solids and decanter liquid, wherein a contherm cooker has been previously used.
• This equipment is not preferred within the embodiments of this invention, as a large proportion of lipids remain in the decanter solids, and the lipids contained in the decanter liquid are emulsified.
• Krill oil recovery using this equipment was very low and the resulting krill meal has a high fat content, specifically over 20% when obtained in the krill fatty period.
• the obtained decanter liquid is passed through a separator centrifuge and then through a purifier separator centrifuge, for obtaining stickwater and a krill oil enriched with neutral lipids with astaxanthin and substantially free or without (or no detectable) phospholipids.
• the obtained stickwater has a low fat content, with a maximum of about 0.3-0.5%, in a non- emulsified form suitable for further processing (concentrate production) and sludge.
• the process for obtaining the neutral lipid-enriched oil has an exclusive and separated line including: separator centrifuge, purifier separator centrifuge, pumps, piping, heat exchangers, tanks and packaging station.
• the decanter solids phase are fed to a twin-screw press using a screw pump or a screw conveyor or other feeding system wherein agitation does not occur.
• the decanter solids phase are pressed using twin screw press with high pressing force or using another pressing system to release the oil with phospholipids linked to the denatured protein according to the production line for the product of the present invention.
• the pressing step is carried out by continuous pressing at a full feeding condition using a 2-10 lpm speed, and more preferably 3-6 rpm and a decanter solids temperature feeding of 90- 96°C and more preferably 93-95°C.
• the pressing system is not particularly restricted.
• the decanter solids phase keep all the phospholipids inside of the coagulated protein, then a strong pressing of the decanter solids release an important percentage of the phospholipids to the press liquid.
• the moisture of this press cake is about 45-55%, preferably 48-53%, Table 3 shows the lipid and moisture content from the press cake of the present invention at different feeding levels of the twin press in the krill fatty period.
• tins press liquid has a high fat content in the range of about 3-25%, preferably 5-20% and more preferably 8-17% (wet base), depending on the seasonal lipid content of krill and if it is not in an emulsified form.
• the fat content in this press liquid is lower than 0.5-3% (wet base) depending on the lipid content of krill and if it is not in an emulsified form.
• a dried complex with oil containing phospholipids with DHA and EPA, proteins and astaxanthin obtained by drying the press liquid "as-is" without centrifuge separation.
• Such dried complex corresponds to a human-grade krill-related product for being used in many human health applications.
• a synergic action of the two-phase decanter and further pressing with twin-screw press or another strong pressing system is required to release the phospholipids with DHA and EPA in the oil, mixed with astaxanthin and neutral lipids.
• the press liquid at a temperature of about 25-121°C, preferably 50-110°C, more preferably 80-100°C and even more preferably 90-96°C, is pumped to the separator centrifuge, using a screw pump or other feeding system, avoiding agitation, wherein the krill oil with phospholipids with DHA and EPA mixed with astaxanthin and neutral lipids is separated.
• the processing speed in the centrifuge separator operates at 4.000-8.000 rpm, more preferably at 4.600-6.800 rpm, with an automatic periodic discharge of solids.
• the oil separator centrifuge is not particularly restricted, i.e any centrifuge equipment satisfying the indicated conditions is suitable for being used.
• This krill oil is once more centrifuged through a purifier separator to clarify it, operating at a processing speed of 5.000-10.000 rpm, more preferably at 6.000-8.200 rpm, with an automatic periodic discharge of solids for later being packaged.
• the purifier separator centrifuge is not particularly restricted, i.e any centrifuge equipment satisfying the indicated conditions is suitable for being used.
• the krill oil with phospholipids with DHA and EPA mixed with astaxanthin and neutral lipids, product of the present invention has an exclusive and separated oil process line including: a separator centrifuge, a purifier separator, pumps, piping, heat exchangers, tanks and a packaging station, completely different and separated from the other oil line with neutral lipid from the decanter liquid phase.
• Examples 3 and 4 shows the characteristics of krill oils obtained in the present invention:
• the debutral lipid enriched krill oil of the present invention is also useful for health human application having a content of:
• - neutral lipids from 50 to 100% w/w, more specifically from 60 to 100% w/w, and more specifically from 70 to 100% w/w,
• - DHA and EPA content are from 2 to 45% w/w, more specifically from 2 to 40% w/w, and more specifically from 5 to 35% w/w,
• - Phospholipids content is lower than 10% w/w, more specifically lower than 5% w/w, and even more specifically lower than 2% w/w,
• Astaxanthin content is from 200 to 1.500 mg/kg, more specifically from 300 to 1200 mg/kg, and even more specifically from 400 to 1.000 mg/kg.
• the phospholipids enriched krill oil of the present invention can be useful for health human applications, having a content of:
• - DHA and EPA content is from 10 to 70% w/w, more specifically from 15 to 60% w/w, and even more specifically from 20 to 55% w/w,
• - Neutral lipids content is from 30 to 70% w/w, more specifically from 40% to 65% w/w, and even more specifically from 45 to 65% w/w
• - Astaxanthin content is from 200 to 1.500 mg/kg, more specifically from 300 to 1.200 mg/kg, and even more specifically from 400 to 1.000 mg/kg.
• compositions for both oil products obtained through the process of the present invention, these oils are suitable for health human applications.
• the process of the present invention provides a krill oil product containing DHA and EPA in the phospholipids fraction with astaxanthin and neutral lipids, which is produced through a different process, which is new and improved, regarding all those krill oils obtained through processes involving solvent extraction and/or using supercritical fluid extraction or through thermal fractionation and centrifugation; additionally, the resulting krill meal, in any Antarctic krill season, will have a maximum fat content of 15%, a minimum protein content of 60 % for a maximum moisture content of 10%.
• krill oils obtained with the procedure disclosed in the present invention can be stabilized by the use of antioxidants and/or preservatives and or with a nitrogen-barred layer.
• krill oils can be stored within plastic or metal containers, necessarily suitable for food-grade, pharmaceutical-grade and or cosmetic/grade applications, in special in stainless steel containers, at room temperature or refrigerated, suitably protected from light.
• the present invention provides uses of krill oils for
• compositions for being used as a dietary supplement and/or nutraceutical product.
• This invention also discloses pharmaceutical compositions comprising an effective amount of krill oil and at least one pharmaceutically acceptable transporter, excipient, stabilizer, diluents and/or adjuvant.
• said krill oil compositions are suitable as photoprotectors.
• Said photoprotectors can be formulated as tanning creams and/or tanning oils.
• said krill oil can be used to elaborate cosmetic products.
• Said cosmetic products are, but no limited to, moisture creams, powder make ups, powder eye shadows, cream eye shadows compact powders and lipsticks
• said krill oil compositions can be effectively used for decreasing cholesterol plasma levels, inhibiting platelet adhesion, inhibiting artery plaque formation, preventing hypertension, controlling arthritis symptoms, preventing skin cancer, enhancing transdermal transport, reducing the symptoms of premenstrual symptoms or controlling blood glucose levels in a patient.
• nutraceuticals, pharmaceuticals and cosmetics comprising the phospholipids-enriched krill oil are also embraced by the present invention.
• Table 1 Lipid and moisture content of decanter solids and decanter liquids obtained with krill captured during South Antarctic's Krill fatty period using a cooker with indirect and direct steam heating system with screw conveyor operating at a low rotation speed
• the cooker screw conveyor speed was set at 7-8 rpm.
• the cooked krill was pumped to the two-phase decanter using a screw pump.
• continuous working cooker with screw conveyor used live steam to increase the krill temperature from about 0°C to 93-95°C.
• the cooker screw conveyor speed was set at 7-8 rpm.
• the cooked krill was pumped to a two-phase decanter.
• the decanter liquid phase was collected into tanks at a temperature of 93-96°C, from wherein it was pumped with a screw pump to the separator centrifuge at a speed set at 4.600 rpm and immediately thereafter passed to a purifier separator at a speed set at 6.100 rpm, for obtaining a krill oil with neutral lipids without phospholipids.
• Example 3 shows this neutral lipids oil composition and characteristics.
• the decanter solid phase was pressed in a twin-screw press resulting in a press liquid phase and press cake phase. Table N° 6 shows the composition obtained from these two phases.
• Example 5 shows the krill meal composition obtained from this test.
• Example 4 shows the composition characteristics of this krill oil with DHA and EPA linked to the phospholipids fraction obtained from the present experiment.
• This example shows an estimate mass balance of a production line for the product of the present invention when raw krill is within the season when fat content is high (estimated at 5%) although not necessarily the highest fat content found in raw South Antarctic Krill and without the addition or recovery of stick water.
• the following tables are an estimated mass balance of the process of the present invention without stick water recovery, utilizing raw krill with average-high fat content (around 5% w/w).
• the following tables shows an estimate mass balance of a production line for the product of the present invention when raw il is within the season when fat content is high (estimated at 5%) although not necessarily the highest fat content found in raw South Antarctic Krill and with the addition or recovery of stickwater .
• composition of the neutral lipid enriched krill oil of the present invent [0136] Composition of the neutral lipid enriched krill oil of the present invent
• composition of the phospholipids' enriched krill oil of the present invent [0140] Composition of the phospholipids' enriched krill oil of the present invent
• Lipid class composition of lipid samples and fatty acid compositions of individual lipids were determined by high performance thin-layer chromatography (HPTLC) and quantitation using a scanning densitometry according to Henderson and Tocher (Henderson, R. J. and Tocher, D. R. (1992) Thin-layer chromatography. In Lipid Analysis: A Practical Approach (Hamilton, R. J., and Hamilton, S., eds.) pp. 65-111, Oxford University Press, Oxford).
• Dietary supplement (nutraceutical/dietary) based on krill oil.
• Such food was formulated in cookie form elaborated using krill oil, krill meal or krill dried complex.
• krill oil krill meal
• krill dried complex krill dried complex.
• Quaker was mixed with 100 g of flour, 500 g of sugar, 1 egg, 150 mL of krill oil of this invention and 10 mL of vanilla extract. Once completely homogenized, the cookies were molded weighing each 25 g, and were baked at 160°C for 15 min. As longer cooking times destroys the astaxanthin.
• the amount of cookies used in the diets will depend on the amount of essential fatty acids such as 18:2 and 18:3 required, and the necessary calories.
• the krill oil prepared as described in the examples 3 and 4 can be used for the preparation of tanning creams and tanning oils for solar protection.
• tanning oil that contains krill oil as the unique sun-blocking agent.
• krill oil has several biological activities, such as being a pigmentant,
• Titanium dioxide 1,9 g
• Krill and/or marine oil has been shown to decrease cholesterol in vivo. It also inhibits platelet adhesion and plaque formation and reduces vascular endothelial inflammation in a patient. It can offer hypertension prophylaxis. It prevents oxidation of low-density lipoprotein. It may have an inhibitory effect on the secretion of VLDL due to increased intracellular degradation of apo B-100. It also offers a post-myocardial infarction prophylaxis because of its ability to decrease CIII apolipoprotein B, to decrease CIII non- apolipoprotein B lipoproteins and to increase antithrombin ⁇ levels.
• Krill and/or marine oil is suitable for prophylactic usage against cardiovascular disease in human where cardiovascular disease relates to coronary artery disease, hyperlipidemia, hypertension, ischemic disease (relating to angina, myocardial infarction, cerebral ischemia, shock without clinical or laboratory evidence of ischemia, arrhythmia).
• cardiovascular disease relates to coronary artery disease, hyperlipidemia, hypertension, ischemic disease (relating to angina, myocardial infarction, cerebral ischemia, shock without clinical or laboratory evidence of ischemia, arrhythmia).
• a pharmaceutical composition of krill oil of this invention comprises capsules containing 1 mL of krill oil described in examples 3 and 4.
• a pharmaceutical composition of krill dried complex of this invention comprises capsules containing 1 to 5 g of krill dried complex.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Polymers & Plastics (AREA)
• Food Science & Technology (AREA)
• Epidemiology (AREA)
• Dermatology (AREA)
• Wood Science & Technology (AREA)
• Insects & Arthropods (AREA)
• Zoology (AREA)
• Birds (AREA)
• Nutrition Science (AREA)
• Diabetes (AREA)
• Marine Sciences & Fisheries (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Mycology (AREA)
• Molecular Biology (AREA)
• Biophysics (AREA)
• Reproductive Health (AREA)
• Endocrinology (AREA)
• Emergency Medicine (AREA)
• Obesity (AREA)
• Hematology (AREA)
• Immunology (AREA)
• Animal Husbandry (AREA)
• Pregnancy & Childbirth (AREA)

Applications Claiming Priority (1)

Publications (1)

Family

ID=42271883

Family Applications (1)

Country Status (16)

Families Citing this family (43)

Family Cites Families (74)